DOCSLIB.ORG

Estonian Statistics on Medicines 2015

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Estonian Statistics on Medicines 2015 Estonian Statistics on Medicines 2015 ATC code ATC group/Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/day A ALIMENTARY TRACT AND METABOLISM 162,0558 A01 STOMATOLOGICAL PREPARATIONS 0,0746 A01A STOMATOLOGICAL PREPARATIONS 0,0746 A01AB Antiinfectives and antiseptics for local oral treatment 0,0746 A01AB09 Miconazole(O) 7144 g 0,2 g 0,0746 A01AB12 Hexetidine(O) 2339440 ml A01AB81 Neomycin+ Benzocaine(C) 27350 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol(dental) 2548 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride(gingival) 174070 g A01AD81 Lidocaine+ Cetrimide(O) 25910 g A01AD82 Choline salicylate(O) 954976 pieces A01AD83 Lidocaine+ Chamomille extract(O) 353260 g A01AD90 Lidocaine+ Paraformaldehyde(dental) 270 g A02 DRUGS FOR ACID RELATED DISORDERS 43,4851 A02A ANTACIDS 1,0240 A02AD Combinations and complexes of aluminium, calcium and magnesium compounds 1,0240 A02AD81 Aluminium hydroxide+ Magnesium hydroxide(O) 753000 pieces 10 pieces 0,1572 A02AD81 Aluminium hydroxide+ Magnesium hydroxide(O) 2869672 ml 50 ml 0,1198 A02AD82 Aluminium aminoacetate+ Magnesium oxide(O) 218420 pieces 10 pieces 0,0456 A02AD83 Calcium carbonate+ Magnesium carbonate(O) 3358224 pieces 10 pieces 0,7013 A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) 42,4612 A02BA H2-receptor antagonists 2,6453 A02BA02 Ranitidine(O) 376819,5 g 0,3 g 2,6229 A02BA02 Ranitidine(P) 3217,5 g 0,3 g 0,0224 A02BC Proton pump inhibitors 39,8159 A02BC01 Omeprazole(O) 251567,44 g 0,02 g 26,2662 A02BC02 Pantoprazole(O) 140586,18 g 0,04 g 7,3393 A02BC02 Pantoprazole(P) 183,96 g 0,04 g 0,0096 A02BC03 Lansoprazole(O) 2,52 g 0,03 g 0,0002 A02BC05 Esomeprazole(O) 86368,8 g 0,03 g 6,0119 A02BC05 Esomeprazole(P) 2710,4 g 0,03 g 0,1887 A02BD Combinations for eradication of Helicobacter pylori A02BD08 Bismuth subcitrate+ Tetracycline+ Metronidazole (O) 240 pieces A03 DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS 7,7770 A03A DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS 6,7861 A03AA Synthetic anticholinergics, esters with tertiary amino group 0,8804 A03AA04 Mebeverine(O) 126480 g 0,3 g 0,8804 A03AB Synthetic anticholinergics, quaternary ammonium compounds <0,0001 A03AB02 Glycopyrronium bromide(P) 0,02 g 3 mg <0,0001 A03AD Papaverine and derivatives 4,3615 A03AD01 Papaverine hydrochloride(P) 76,8 g 0,1 g 0,0016 A03AD02 Drotaverine(O) 204204,8 g 0,1 g 4,2642 A03AD02 Drotaverine(P) 4583 g 0,1 g 0,0957 A03AX Other drugs for functional gastrointestinal disorders 1,5442 A03AX13 Simeticone(O) 369736,3862 g 0,5 g 1,5442 A03B BELLADONNA AND DERIVATIVES, PLAIN 0,1094 A03BA Belladonna alkaloids, tertiary amines 0,0896 A03BA01 Atropine(O, P) 32,87 g 0,0015 g 0,0458 A03BA01 Atropine(P) 31,52 g 0,0015 g 0,0439 A03BB Belladonna alkaloids, semisynthetic, quaternary ammonium compounds 0,0198 A03BB01 Butylscopolamine(O) 80,8 g 0,06 g 0,0028 A03BB01 Butylscopolamine(P) 482,9 g 0,06 g 0,0168 A03BB01 Butylscopolamine(R) 5,16 g 0,06 g 0,0002 A03F PROPULSIVES 0,8814 A03FA Propulsives 0,8814 A03FA01 Metoclopramide(O) 10048 g 0,03 g 0,6994 A03FA01 Metoclopramide(P) 2005,8 g 0,03 g 0,1396 A03FA01 Metoclopramide(R) 2,75 g 0,03 g 0,0002 A03FA03 Domperidone(O) 606,6 g 0,03 g 0,0422 A04 ANTIEMETICS AND ANTINAUSEANTS 0,1377 A04A ANTIEMETICS AND ANTINAUSEANTS 0,1377 A04AA Serotonin (5-HT3) antagonists 0,1215 A04AA01 Ondansetron(O) 7,76 g 0,016 g 0,0010 A04AA01 Ondansetron(P) 31,78 g 0,016 g 0,0041 A04AA02 Granisetron(O) 57,07 g 0,002 g 0,0596 A04AA02 Granisetron(P) 81,515 g 0,003 g 0,0567 A04AA05 Palonosetron(P) 0,0013 g 0,25 mg <0,0001 1/32 Estonian Statistics on Medicines 2015 A04AD Other antiemetics 0,0162 A04AD12 Aprepitant(O) 485,07 g 0,095 g 0,0107 A04AD81 Fosaprepitant(P) 252,15 g 0,095 g 0,0055 A05 BILE AND LIVER THERAPY 2,7750 A05A BILE THERAPY 0,4669 A05AA Bile acid preparations 0,4669 A05AA02 Ursodeoxycholic acid(O) 167700 g 0,75 g 0,4669 A05B LIVER THERAPY, LIPOTROPICS 2,3081 A05BA Liver therapy 2,3081 A05BA03 Silymarin(O) 3700570 pieces A05BA80 Essential phospholipids(O) 3315870 pieces 3 pieces 2,3081 A05BA80 Essential phospholipids(P) 2875 pieces A06 DRUGS FOR CONSTIPATION 15,0814 A06A DRUGS FOR CONSTIPATION 15,0814 A06AB Contact laxatives 7,1883 A06AB02 Bisacodyl(O) 15666,2 g 0,01 g 3,2714 A06AB02 Bisacodyl(R) 859 g 0,01 g 0,1794 A06AB06 Senna glycosides(O) 12860 pieces 1 pieces 0,0269 A06AB08 Sodium picosulfate(O) 8884,8 g 0,005 g 3,7107 A06AD Osmotically acting laxatives 7,0790 A06AD11 Lactulose(O) 21892844,5 g 6,7 g 6,8234 A06AD15 Macrogol(O) 1224000 g 10 g 0,2556 A06AD80 Macrogol+ Sodium citrate+ Citric acid+ Sodium chloride+ Potassium chloride(O) 21800 ml A06AD81 Sodium sulphate, anhydrous+ Potassium chloride+ Sodium chloride+ Macrogol+ Sodium hydrogen 58672 pieces carbonate(O) A06AD84 Macrogol+ Sodium chloride+ Sodium hydrogen carbonate+ Potassium chloride(O) 5048 pieces A06AD85 Sodium sulphate, anhydrous+ magnesium sulfate heptahydrate+ Potassium sulphate(O) 554048 ml A06AG Enemas 0,8141 A06AG11 Laurilsulfate, incl. combinations+ Sorbitol+ Sodium citrate(R) 389856 pieces 1 pieces 0,8141 A06AX Other drugs for constipation A06AX01 Glycerol(R) 200 pieces A07 ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS 3,6743 A07A INTESTINAL ANTIINFECTIVES 0,0002 A07AA Antibiotics 0,0002 A07AA02 Nystatin(O) 80000000 U 1500000 U 0,0001 A07AA12 Fidaxomicin(O) 8 g 0,4 g <0,0001 A07B INTESTINAL ADSORBENTS 0,4385 A07BC Other intestinal adsorbents 0,4385 A07BC05 Diosmectidum(O) 1889820 g 9 g 0,4385 A07C ELECTROLYTES WITH CARBOHYDRATES A07CA Oral rehydration salt formulations A07CA80 Sodium chloride+ Potassium chloride+ Sodium citrate+ Glucose(O) 51600 pieces A07D ANTIPROPULSIVES 0,9296 A07DA Antipropulsives 0,9296 A07DA03 Loperamide(O) 4451,832 g 0,01 g 0,9296 A07E INTESTINAL ANTIINFLAMMATORY AGENTS 1,7964 A07EA Corticosteroids acting locally 0,0005 A07EA06 Budesonide(O) 2,04 g 0,009 g 0,0005 A07EA06 Budesonide(R) 1,0171 g A07EC Aminosalicylic acid and similar agents 1,7959 A07EC01 Sulfasalazine(O) 822500 g 2 g 0,8588 A07EC02 Mesalazine(O) 619470 g 1,5 g 0,8624 A07EC02 Mesalazine(R) 53696 g 1,5 g 0,0748 A07F ANTIDIARRHEAL MICROORGANISMS 0,5097 A07FA Antidiarrheal microorganisms 0,5097 A07FA02 Saccharomyces boulardii(O) 244062,5 g 1 g 0,5097 A07X OTHER ANTIDIARRHEALS A07XA Other antidiarrheals A07XA04 Racecadotril(O) 2500,52 g A08 ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS 0,0232 A08A ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS 0,0232 A08AB Peripherally acting antiobesity products 0,0232 A08AB01 Orlistat(O) 4001,76 g 0,36 g 0,0232 A09 DIGESTIVES, INCL. ENZYMES 1,4096 A09A DIGESTIVES, INCL. ENZYMES 1,4096 A09AA Enzyme preparations 1,4092 A09AA02 Lipase+ Amylase+ Protease(O) 2699410 pieces 4 pieces 1,4092 A09AC Enzyme and acid preparations, combinations 0,0004 A09AC80 Pepsin+ Betaine(O) 600 pieces 3 pieces 0,0004 A10 DRUGS USED IN DIABETES 59,5203 A10A INSULINS AND ANALOGUES 15,9158 2/32 Estonian Statistics on Medicines 2015 A10AB Insulins and analogues for injection, fast-acting 6,0793 A10AB01 Insulin (human)(P) 933000 U 40 U 0,0487 A10AB04 Insulin lispro(P) 24589500 U 40 U 1,2837 A10AB05 Insulin aspart(P) 77374500 U 40 U 4,0393 A10AB06 Insulin glulisine(P) 13552500 U 40 U 0,7075 A10AC Insulins and analogues for injection, intermediate-acting 0,1658 A10AC01 Insulin (human)(P) 3175500 U 40 U 0,1658 A10AD Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting 1,6434 A10AD04 Insulin lispro(P) 11839500 U 40 U 0,6181 A10AD05 Insulin aspart(P) 19639500 U 40 U 1,0253 A10AE Insulins and analogues for injection, long-acting 8,0274 A10AE04 Insulin glargine(P) 81476250 U 40 U 4,2535 A10AE05 Insulin detemir(P) 72289500 U 40 U 3,7739 A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS 43,6045 A10BA Biguanides 19,7255 A10BA02 Metformin(O) 18892341 g 2 g 19,7255 A10BB Sulfonylureas 16,2440 A10BB07 Glipizide(O) 1574,55 g 0,01 g 0,3288 A10BB09 Gliclazide(O) 260622,6 g 0,06 g 9,0706 A10BB12 Glimepiride(O) 6555,51 g 0,002 g 6,8446 A10BD Combinations of oral blood glucose lowering drugs 3,1192 A10BD07 Metformin+ Sitagliptin(O) 1725248 pieces 2 pieces 1,8013 A10BD08 Metformin+ Vildagliptin(O) 470220 pieces 2 pieces 0,4910 A10BD10 Metformin+ Saxagliptin(O) 262440 pieces 2 pieces 0,2740 A10BD11 Metformin+ Linagliptin(O) 504600 pieces 2 pieces 0,5269 A10BD15 Metformin+ Dapagliflozin(O) 24976 pieces 2 pieces 0,0261 A10BD20 Metformin+ Empagliflozin(O) 14220 pieces A10BG Thiazolidinediones 0,1100 A10BG03 Pioglitazone(O) 1580,88 g 0,03 g 0,1100 A10BH Dipeptyl peptidase 4 (DPP-4) inhibitors 2,9503 A10BH01 Sitagliptin(O) 74948,3 g 0,1 g 1,5651 A10BH02 Vildagliptin(O) 6387 g 0,1 g 0,1334 A10BH03 Saxagliptin(O) 495,9 g 5 mg 0,2071 A10BH04 Alogliptin(O) 51,8 g A10BH05 Linagliptin(O) 2501,55 g 5 mg 1,0448 A10BX Other blood glucose lowering drugs, excl. insulins 1,4554 A10BX04 Exenatide(P) 7,6003 g 0,286 mg 0,0555 A10BX07 Liraglutide(P) 550,224 g 1,2 mg 0,9575 A10BX09 Dapagliflozin(O) 1449,75 g 10 mg 0,3027 A10BX10 Lixisenatide(P) 1,338 g 20 mcg 0,1397 A10BX12 empagliflozin(O) 1124,25 g A11 VITAMINS 16,3331 A11A MULTIVITAMINS, COMBINATIONS 2,0093 A11AA Multivitamins with minerals 2,0093 A11AA03 Multivitamins+ Mineral elements(O) 962190 pieces 1 pieces 2,0093 A11B MULTIVITAMINS, PLAIN <0,0001 A11BA Multivitamins, plain <0,0001 A11BA80 Multivitamins(O) 150 ml 10 ml <0,0001 A11C VITAMIN A AND D, INCL.
Load more

Recommended publications
  • Medical Review(S) Clinical Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 200327 Priority or Standard Standard Submit Date(s) December 29, 2009 Received Date(s) December 30, 2009 PDUFA Goal Date October 30, 2010 Division / Office Division of Anti-Infective and Ophthalmology Products Office of Antimicrobial Products Reviewer Name(s) Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD Review Completion October 29, 2010 Date Established Name Ceftaroline fosamil for injection (Proposed) Trade Name Teflaro Therapeutic Class Cephalosporin; ß-lactams Applicant Cerexa, Inc. Forest Laboratories, Inc. Formulation(s) 400 mg/vial and 600 mg/vial Intravenous Dosing Regimen 600 mg every 12 hours by IV infusion Indication(s) Acute Bacterial Skin and Skin Structure Infection (ABSSSI); Community-acquired Bacterial Pneumonia (CABP) Intended Population(s) Adults ≥ 18 years of age Template Version: March 6, 2009 Reference ID: 2857265 Clinical Review Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD NDA 200327: Teflaro (ceftaroline fosamil) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 9 1.1 Recommendation on Regulatory Action ........................................................... 10 1.2 Risk Benefit Assessment.................................................................................. 10 1.3 Recommendations for Postmarketing Risk Evaluation and Mitigation Strategies ........................................................................................................................
    [Show full text]
  • Research Journal of Pharmaceutical, Biological and Chemical Sciences
    ISSN: 0975-8585 Research Journal of Pharmaceutical, Biological and Chemical Sciences Formulation and Evaluation of Floating Drotaverine Hydrochloride Tablets Using Factorial Design Om Prakash*, S Saraf, M Rahman, Neeraj Agnihotri, and Vinay Pathak Department of Industrial chemistry, Integral University, Lucknow. Uttar Pradesh, India. ABSTRACT The main aim of this study was to optimize and evaluate the floating tablets of Drotaverine HCl that prolong the gastric residence time, increasing drug bioavailability and control pain for longer duration by oral administration. A floating drug delivery system(FDDS) was developed using gas forming agent like sodium bicarbonate, citric acid polymers like hydroxypropyl methyl cellulose(HPMC), Sod CMC, Carbopol-934P, PVP K-30. In 32 factorial design amount of HPMC(X1) and gas generating agents(X2) were selected as independent variable and % drug release for 30min,1h, 2h,4h,6h, 8h,12h, 16h , 24h and floating lag time (FLT) were taken as dependent variable. The floating tablet formulations were evaluated for Bulk density (gm/cm3), Tapped density(gm/cm3), Hausner ratio(HR), Carr index, Angle of repose, flow property, assay, in-vitro drug release, hardness, friability,weight variation. The results of in vitro release studies showed that the optimized formulation (F9) could sustain drug release (98.74%) for 24h and remain buoyant for more than 24h. The combination of hydrophilic (HPMC) and hydrophobic (carbopol-934P) polymer provides a better option for 24h release action, bioavailability, stability of tablets at 400C/75%RH, of optimized formulation was carried for one month and no significant change was observed. Keywords: floating drug delivery system(FDDS), Drotaverine HCl, gas generating agents, floating lag time (FLT), hydrophilic (HPMC) and hydrophobic (carbopol-934P) polymer.
    [Show full text]
  • PMBJP Product.Pdf
    Sr. Drug Generic Name of the Medicine Unit Size MRP Therapeutic Category No. Code Analgesic & Antipyretic / Muscle 1 1 Aceclofenac 100mg and Paracetamol 325 mg Tablet 10's 10's 8.00 relaxants Analgesic & Antipyretic / Muscle 2 2 Aceclofenac Tablets IP 100mg 10's 10's 4.37 relaxants Acetaminophen 325 + Tramadol Hydrochloride 37.5 film Analgesic & Antipyretic / Muscle 3 4 10's 8.00 coated Tablet 10's relaxants Analgesic & Antipyretic / Muscle 4 5 ASPIRIN Tablets IP 150 mg 14's 14's 2.70 relaxants DICLOFENAC 50 mg+ PARACETAMOL 325 mg+ Analgesic & Antipyretic / Muscle 5 6 10's 11.30 CHLORZOXAZONE 500 mg Tablets 10's relaxants Diclofenac Sodium 50mg + Serratiopeptidase 10mg Tablet Analgesic & Antipyretic / Muscle 6 8 10's 12.00 10's relaxants Analgesic & Antipyretic / Muscle 7 9 Diclofenac Sodium (SR) 100 mg Tablet 10's 10's 6.12 relaxants Analgesic & Antipyretic / Muscle 8 10 Diclofenac Sodium 25mg per ml Inj. IP 3 ml 3 ml 2.00 relaxants Analgesic & Antipyretic / Muscle 9 11 Diclofenac Sodium 50 mg Tablet 10's 10's 2.90 relaxants Analgesic & Antipyretic / Muscle 10 12 Etoricoxilb Tablets IP 120mg 10's 10's 33.00 relaxants Analgesic & Antipyretic / Muscle 11 13 Etoricoxilb Tablets IP 90mg 10's 10's 25.00 relaxants Analgesic & Antipyretic / Muscle 12 14 Ibuprofen 400 mg + Paracetamol 325 mg Tablet 10's 15's 5.50 relaxants Analgesic & Antipyretic / Muscle 13 15 Ibuprofen 200 mg film coated Tablet 10's 10's 1.80 relaxants Analgesic & Antipyretic / Muscle 14 16 Ibuprofen 400 mg film coated Tablet 10's 15's 3.50 relaxants Analgesic & Antipyretic
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmacology on Your Palms CLASSIFICATION of the DRUGS
    Pharmacology on your palms CLASSIFICATION OF THE DRUGS DRUGS FROM DRUGS AFFECTING THE ORGANS CHEMOTHERAPEUTIC DIFFERENT DRUGS AFFECTING THE NERVOUS SYSTEM AND TISSUES DRUGS PHARMACOLOGICAL GROUPS Drugs affecting peripheral Antitumor drugs Drugs affecting the cardiovascular Antimicrobial, antiviral, Drugs affecting the nervous system Antiallergic drugs system antiparasitic drugs central nervous system Drugs affecting the sensory Antidotes nerve endings Cardiac glycosides Antibiotics CNS DEPRESSANTS (AFFECTING THE Antihypertensive drugs Sulfonamides Analgesics (opioid, AFFERENT INNERVATION) Antianginal drugs Antituberculous drugs analgesics-antipyretics, Antiarrhythmic drugs Antihelminthic drugs NSAIDs) Local anaesthetics Antihyperlipidemic drugs Antifungal drugs Sedative and hypnotic Coating drugs Spasmolytics Antiviral drugs drugs Adsorbents Drugs affecting the excretory system Antimalarial drugs Tranquilizers Astringents Diuretics Antisyphilitic drugs Neuroleptics Expectorants Drugs affecting the hemopoietic system Antiseptics Anticonvulsants Irritant drugs Drugs affecting blood coagulation Disinfectants Antiparkinsonian drugs Drugs affecting peripheral Drugs affecting erythro- and leukopoiesis General anaesthetics neurotransmitter processes Drugs affecting the digestive system CNS STIMULANTS (AFFECTING THE Anorectic drugs Psychomotor stimulants EFFERENT PART OF THE Bitter stuffs. Drugs for replacement therapy Analeptics NERVOUS SYSTEM) Antiacid drugs Antidepressants Direct-acting-cholinomimetics Antiulcer drugs Nootropics (Cognitive
    [Show full text]
  • Workbook Psychiatry and Narcology
    Kharkiv National Medical University Department of Psychiatry, Narcology and Medical Psychology WORKBOOK MANUAL FOR INDIVIDUAL WORK FOR MEDICAL STUDENTS PSYCHIATRY AND NARCOLOGY (Part 2) Student ___________________________________________________________ Faculty _________________________________________________________ Course _________________ Group _____________________________________ Kharkiv 2019 Затверджено вченою радою ХНМУ Протокол №5 від 23.05.2019 р. Psychiatry (Part 2) : workbook manual for individual work of students / I. Strelnikova, G. Samardacova, К. Zelenska – Kharkiv, 2019. – 103 p. Копіювання для розповсюдження в будь-якому вигляді частин або повністю можливо тільки з дозволу авторів навчального посібника. CLASS 7. NEUROTIC DISORDERS. CLINICAL FORMS. TREATMENT AND REHABILITATION. POSTTRAUMATIC STRESS DISORDER. TREATMENT AND REHABILITATION. Psychogenic diseases are a large and clinically varied group of diseases resulting from an effect of acute or long-term psychic traumas, which manifest themselves by both mental and somatoneurological disorders and, as a rule, are reversible. Psychogenic diseases are caused by a psychic trauma, i.e. some events which affect significant aspects of existence of the human being and result in deep psychological feelings. These may be subjectively significant events, i.e. those which are pathogenic for the majority of people. Besides, the psyche may be traumatized by conventionally pathogenic events, which cause feelings in an individual because of his peculiar hierarchy of values. Unfavorable psychogenic effects on the human being cause stress in him, i.e. a nonspecific reaction at the physiological, psychological and behavioural levels. Stress may exert some positive, mobilizing influence, but may result in disorganization of the organism activity. The stress, which exerts a negative influence and causes various disturbances and even diseases, is termed distress. Classification of neurotic disorders I.
    [Show full text]
  • Minutes of PRAC Meeting on 09-12 July 2018
    6 September 2018 EMA/PRAC/576790/2018 Inspections, Human Medicines Pharmacovigilance and Committees Division Pharmacovigilance Risk Assessment Committee (PRAC) Minutes of the meeting on 09-12 July 2018 Chair: June Raine – Vice-Chair: Almath Spooner Health and safety information In accordance with the Agency’s health and safety policy, delegates were briefed on health, safety and emergency information and procedures prior to the start of the meeting. Disclaimers Some of the information contained in the minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scope listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also change during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised. Of note, the minutes are a working document primarily designed for PRAC members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006, Rev. 1). 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2018.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0296.191 A1 PATEL Et Al
    US 20140296.191A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0296.191 A1 PATEL et al. (43) Pub. Date: Oct. 2, 2014 (54) COMPOSITIONS OF PHARMACEUTICAL (52) U.S. Cl. ACTIVES CONTAINING DETHYLENE CPC ............... A61K 47/10 (2013.01); A61 K9/0019 GLYCOL MONOETHYLETHER OR OTHER (2013.01); A61 K9/0048 (2013.01); A61 K ALKYL DERVATIVES 45/06 (2013.01) USPC ........... 514/167: 514/177; 514/178: 514/450; (71) Applicant: THEMIS MEDICARE LIMITED, 514/334: 514/226.5: 514/449; 514/338; Mumbai (IN) 514/256; 514/570; 514/179; 514/174: 514/533; (72) Inventors: Dinesh Shantilal PATEL, Mumbai (IN); 514/629; 514/619 Sachin Dinesh PATEL, Mumbai (IN); Shashikant Prabhudas KURANI, Mumbai (IN); Madhavlal Govindlal (57) ABSTRACT PATEL, Mumbai (IN) (73) Assignee: THEMIS MEDICARE LIMITED, The present invention relates to pharmaceutical compositions Mumbai (IN) of various pharmaceutical actives, especially lyophilic and hydrophilic actives containing Diethylene glycol monoethyl (21) Appl. No.: 14/242,973 ether or other alkyl derivatives thereofas a primary vehicle and/or to pharmaceutical compositions utilizing Diethylene (22) Filed: Apr. 2, 2014 glycol monoethyl ether or other alkyl derivatives thereofas a primary vehicle or as a solvent system in preparation of Such (30) Foreign Application Priority Data pharmaceutical compositions. The pharmaceutical composi Apr. 2, 2013 (IN) ......................... 1287/MUMA2013 tions of the present invention are safe, non-toxic, exhibits enhanced physical stability compared to conventional formu Publication Classification lations containing such pharmaceutical actives and are Suit able for use as injectables for intravenous and intramuscular (51) Int. Cl. administration, as well as for use as a preformed solution/ A647/ (2006.01) liquid for filling in and preparation of capsules, tablets, nasal A6 IK 45/06 (2006.01) sprays, gargles, dermal applications, gels, topicals, liquid oral A6 IK9/00 (2006.01) dosage forms and other dosage forms.
    [Show full text]
  • Efficacy and Safety of Drotaverine Hydrochloride in Irritable Bowel Syndrome: a Randomized Double-Blind Placebo- Controlled Study Ramesh R
    Original Article Efficacy and Safety of Drotaverine Hydrochloride in Irritable Bowel Syndrome: A Randomized Double-Blind Placebo- Controlled Study Ramesh R. Rai, Manisha Dwivedi1, Nirmal Kumar2 Departments of Gastroenterology, Fortis-Escorts ABSTRACT Hospital, Jaipur, Rajasthan, 1 Gastroenterolgy, M.L.N. Backgrounds/Aims: To study the efficacy and safety of drotaverine hydrochloride (HCl) 80 mg tablet given Medical College, Allahabad, thrice a day in the symptomatic relief of patients with irritable bowel syndrome (IBS). Patients and Methods: The 2 Uttar Pradesh, Gastroenterolgy, study was a multicentric, randomized, double-blind, placebo-controlled parallel group study performed Sri Balaji Action Medical at three centers. The patients who fulfilled Rome II Criteria of IBS were included in the study. A total of Institute, New Delhi, India 180 patients with IBS were randomized to drotaverine and placebo treatment groups. Abdominal pain and Address for correspondence: stool frequency were measured every week in both the groups for all the 4 weeks of treatment duration. Subject Dr. Ramesh Roop Rai, H-6, Global Assessment of Relief (SGA) of IBS symptoms was assessed at the end of the study. Appropriate statistical Janpath, Shyam Nagar, analysis was done using SPSS software. Statistical Analysis Used: Mann–Whitney U-test (two-tailed), Jaipur - 302 019, Wilcoxon signed ranks test, and McNemar tests. Results: Pain frequency decreased significantly (P < 0.01) Rajasthan, India. in 22 (25.9%), 51 (60%), and 66 (77.7%) patients in the drotaverine group, at the end of 2nd, 3rd, and 4th weeks, E-mail: [email protected] respectively, as compared with 8 (9.4%), 18 (21.2%), and 26 (30.6%) in the placebo group.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,283,192 B2 Mullen Et Al
    US009283192B2 (12) United States Patent (10) Patent No.: US 9,283,192 B2 Mullen et al. (45) Date of Patent: Mar. 15, 2016 (54) DELAYED PROLONGED DRUG DELIVERY 2009. O1553.58 A1 6/2009 Diaz et al. 2009,02976O1 A1 12/2009 Vergnault et al. 2010.0040557 A1 2/2010 Keet al. (75) Inventors: Alexander Mullen, Glasgow (GB); 2013, OO17262 A1 1/2013 Mullen et al. Howard Stevens, Glasgow (GB); Sarah 2013/0022676 A1 1/2013 Mullen et al. Eccleston, Scotstoun (GB) FOREIGN PATENT DOCUMENTS (73) Assignee: UNIVERSITY OF STRATHCLYDE, Glasgow (GB) EP O 546593 A1 6, 1993 EP 1064937 1, 2001 EP 1607 O92 A1 12/2005 (*) Notice: Subject to any disclaimer, the term of this EP 2098 250 A1 9, 2009 patent is extended or adjusted under 35 JP HO5-194188 A 8, 1993 U.S.C. 154(b) by 0 days. JP 2001-515854. A 9, 2001 JP 2001-322927 A 11, 2001 JP 2003-503340 A 1, 2003 (21) Appl. No.: 131582,926 JP 2004-300148 A 10, 2004 JP 2005-508326 A 3, 2005 (22) PCT Filed: Mar. 4, 2011 JP 2005-508327 A 3, 2005 JP 2005-508328 A 3, 2005 (86). PCT No.: PCT/GB2O11AOOO3O7 JP 2005-510477 A 4/2005 JP 2008-517970 A 5, 2008 JP 2009-514989 4/2009 S371 (c)(1), WO WO99,12524 A1 3, 1999 (2), (4) Date: Oct. 2, 2012 WO WOO1 OO181 A2 1, 2001 WO WOO3,O266.15 A2 4/2003 (87) PCT Pub. No.: WO2011/107750 WO WOO3,O26625 A1 4/2003 WO WO 03/026626 A2 4/2003 PCT Pub.
    [Show full text]